ProKidney Corp. (PROK) Stock Score, Valuation & Financial Research
ProKidney Corp. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 27/100.
Quick answer for PROK
ProKidney Corp. currently has a Wall Street Score of 27/100. The stored market price is $1.85. Its financial score is 12/100. Its valuation score is 0/100. The latest WSS change is -1.0 points. These figures are a research snapshot, not a buy or sell recommendation.
What ProKidney Corp. does
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.
PROK financial snapshot
- Wall Street Score:
- 27/100
- Current price:
- $1.85
- Market capitalization:
- $622.1M
- Revenue:
- $818K
- Net income:
- $-86.7M
- Free cash flow:
- $-135.3M
- Cash:
- $74.9M
- Total debt:
- $3.5M
- EPS:
- -0.57
- Financial score:
- 12/100
- Valuation score:
- 0/100
- Revenue score:
- 0/100
What stands out
- Reported year-over-year revenue growth is -0.1%.
- Free cash flow is $-135.3M, showing cash burn in the current stored period.
- The balance sheet shows $74.9M of cash versus $3.5M of total debt, leaving more cash than debt.
- The latest Wall Street Score change is -1.0 points: PROK decreased 1 points because Debt declined by 10 points, Asset declined by 5.1 points.
- The current research record carries a share basis reconciled warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 12/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-13.
How to research PROK
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.